Posted by Michael Wonder on 09 Apr 2020
Liquidia announces FDA acceptance of new drug application for LIQ861 (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension
8 April 2020 - Liquidia Technologies today announced that the US FDA accepted for review the Company’s new drug application seeking marketing approval for LIQ861 for the treatment of pulmonary arterial hypertension.
Under the Prescription Drug User Fee Act, the FDA has set a goal date of 24 November 2020.
